| |OCTOBER 20249MEDIBUDDY & PHILIPS JOIN HANDS TO BRING ADVANCED HEART HEALTH TRACKINGMEDGENOME & TWIST BIOSCIENCE TEAM UP TO DIAGNOSE RARE DISEASESMediBuddy, the biggest digital healthcare platform in India, has partnered with Philips, a global leader in health technology, to transform preventive healthcare in India. For World Heart Day on September 29, the collaboration will provide heart early warning signs detection with Philips HeartPrint.MediBuddy is dedicated to ensuring that all Indians have access to top-notch healthcare by incorporating cutting-edge AI-based longitudinal triaging on their smartphone.While ECGs evaluate the heart's present condition, the Philips HeartPrint acts as a continuous monitoring tool that can predict potential future risks and monitor the progression of heart health over time. This proactive method of managing heart health in India could revolutionize cardiac care by allowing for early intervention and personalized health plans.Satish Kannan, co-founder and CEO, MediBuddy, said, "Our partnership with Philips integrates cutting-edge HeartPrint technology into our platform, revolutionising preventive cardiac care. By providing accessible, advanced tools for cardiac tracking, on the MediBuddy platform accessible through any smart phone we're enabling millions to take control of their heart health, fostering earlier detection and better outcomes for a healthier nation."By simply scanning their finger using their smartphone's camera through the MediBuddy mobile application, users can track key biomarkers that indicate their risk of heart disease, overall health deterioration, heart resilience, and changes in heart function over time, he said. POMedGenome, a prominent worldwide genomics-focused diagnostics and research services company, is joining forces with Twist Bioscience, a fast-growing synthetic biology and genomics company in the US, to create the HOPE for Rare Diseases Programme in India. In the program, economically disadvantaged families can receive discounted whole exome sequencing if they provide the required documentation. The program has a limited duration.The partnership aligns with MedGenome's celebration of ten years of leading genomics breakthroughs in India. Through this collaboration, MedGenome is restating its dedication to providing accessible and cost-effective genetic solutions to all segments of the population. MedGenome will keep following its vision to improve healthcare affordability and accessibility, and will concentrate on using genomics to tackle the significant demand in emerging markets.Twist Bioscience is utilizing the Twist Exome 2.0 in order to assist with this goal. Created to help scientists identify uncommon genetic diseases and inherited cancers, assisting them in gathering high-quality data through reduced sequencing requirements.The collaboration between MedGenome and Twist Bioscience aims to make this technology accessible to people in low-income communities worldwide, offering the necessary genetic information to solve their diagnostic challenges and support healthcare providers in addressing the disease.Despite being accessible for more than ten years, this technology has not become widely used because of its expense, lack of awareness, and absence of insurance coverage, as healthcare in India still requires direct payment. PO
< Page 8 | Page 10 >